North America Theranostics Market

North America Theranostics Market Size & Forecast:

• North America Theranostics Market Size 2025: USD 40.9 Million
• North America Theranostics Market Size 2033: USD 98.38 Million
• North America Theranostics Market CAGR: 11.60%
• North America Theranostics Market Segments: By Type (Radiopharmaceuticals, Companion Diagnostics, Targeted Therapy, Imaging Agents, Biomarkers, Others); By Application (Oncology, Cardiology, Neurology, Infectious Diseases, Rare Diseases, Others); By End-User (Hospitals, Diagnostic Centers, Research Institutes, Pharma, Others); By Technology (PET, SPECT, MRI, CT, Molecular Imaging, Others).

To learn more about this report,  Download Free Sample Report

North America Theranostics Market Summary:

The North America Theranostics Market size is estimated at USD 40.9 Million in 2025 and is anticipated to reach USD 98.38 Million by 2033, growing at a CAGR of 11.60% from 2026 to 2033. 

The north america theranostics market within the advanced healthcare and precision medicine industry will continue to gain definition as clinical practice shifts toward tightly integrated diagnosis and treatment pathways. Healthcare systems throughout the United States and Canada will establish dedicated systems which combine imaging agents and therapeutic compounds because they require accurate biological marker detection.

The approach has been developed because there has been a shift in patient expectations which now drive patients to seek immediate access to customized treatment solutions that eliminate unnecessary testing requirements. Hospitals and specialty clinics will invest in hybrid platforms which enable them to monitor disease progression in real time. The current market conditions show a complete market development because of successful clinical testing and physician acceptance and new reimbursement systems which support treatment methods based on patient outcomes.

This space will experience ongoing technological development which will drive its expansion through molecular imaging and artificial intelligence diagnostic systems and new isotope production methods. North American regulatory agencies will increase their control over drug development processes while they establish faster approval routes for therapies which prove their effectiveness to treat patients. The aging population combined with rising chronic disease rates will create demand patterns which drive healthcare providers to implement solutions that shorten hospital stays and boost treatment accuracy.

The pharmaceutical and biotech industry will establish strategic partnerships to expedite their development processes while maintaining stable production of essential isotopes. The current market will demonstrate how contemporary medical practices have evolved to provide integrated treatment approaches which use data analysis for diagnosis and medical decision-making.

What Has the Impact of Artificial Intelligence Been on the North America Theranostics Market?

The North American theranostics market experiences rapid transformation through artificial intelligence, which establishes new methods for organizations to make decisions by using data and respectively deliver precise healthcare services. The North American theranostics market runs AI applications, which enable researchers to conduct market investigations and data assessments by analyzing extensive clinical and genomic and imaging data collections with both fast processing times and precise results. 

Advanced machine learning models uncover hidden patterns, which enable stakeholders to identify emerging market trends and investment opportunities more effectively. The data-driven method enables pharmaceutical companies and diagnostic firms and healthcare providers to establish strategic plans while making decisions based on scientific evidence.

Artificial intelligence in north america theranostics market operations also plays a crucial role in demand forecasting and trend prediction. Predictive analytics tools analyze historical data, patient demographics, and disease prevalence to anticipate future demand for targeted therapies and diagnostic solutions. The process provides organizations with better inventory management capabilities while minimizing their resource consumption through inventory planning. 

Smart automation improves production efficiency by automating all steps needed for radiopharmaceutical manufacturing and quality control and regulatory compliance. The advancements decrease operational expenses while achieving essential precision and safety requirements that maintain operational standards in theranostics.

AI-powered supply chain optimization solutions enable companies to enhance their logistics operations while decreasing delivery times and maintaining proper medical product shipment schedules in the North American theranostics industry. The AI systems provide organizations with instant tracking capabilities and risk evaluation functions and street optimization tools which help them decrease operational interruptions and financial waste. 

The operational advantages of artificial intelligence lead to innovative development because it enables healthcare professionals to create customized treatment plans that match each patient's unique needs. The North American theranostics market sustains its competitive edge through efficiency and personalized services and innovative solutions which help it succeed in a healthcare sector that increasingly depends on technological advancements.

Key Market Trends & Insights:

• The United States dominates the north america theranostics market, accounting for over 85% market share in 2025 because of its advanced healthcare system. 
• The Canada region experiences its fastest growth rate which will continue until 2030 with a compound annual growth rate that exceeds 9 percent. 
• The market for radiopharmaceuticals ends 2025 with a market share above 60 percent because more people are using targeted cancer treatments. 
• The second largest market share belongs to diagnostic imaging agents which receive support from the increasing use of PET and SPECT scans. 
• The demand for smart automation drives the growth of AI-integrated theranostic platforms which become the fastest expanding market segment between 2025 and 2030.
• The oncology field will hold most application areas with its 70 percent market share during 2025 because of rising cancer cases and the need for specific treatment options.
• The sector of neurology applications has developed into its most rapidly expanding field because of increased research activities focusing on Alzheimer’s and neurodegenerative disease diagnostic methods.
• The North American theranostics market shows its main hospital sector which will reach 55 percent market share by 2025 because hospitals treat more patients and possess better imaging capabilities.
• The end-user group which develops fastest consists of research institutes and specialty clinics which will grow at a rate above 8 percent until 2030.
• The main companies in the market include GE HealthCare and Siemens Healthineers and Novartis AG and Cardinal Health and Bayer AG who operate in multiple countries.

North America Theranostics Market Segmentation

By Type :

The precise targeting of radiopharmaceuticals together with their treatment monitoring abilities enables clinical applications. The use of companion diagnostics enables physicians to choose treatments with better precision. Targeted therapy provides patients with customized treatment options. Imaging agents enable doctors to better track how diseases develop. Biomarkers enable doctors to identify diseases at their initial stage while monitoring patient responses, and research into new biomarker types develops clinical applications through ongoing scientific studies. 

The combination of radiopharmaceuticals and imaging agents establishes a diagnostic system which enables effective treatment methods to develop into future healthcare advancements. The combination of companion diagnostics and biomarkers provides clinical environments with tools that help create accurate medical decisions. The demand for targeted therapy remains steady because healthcare systems now use precision medicine as their primary treatment approach.

By Application: 

The rising number of cancer patients and the demand for accurate medical solutions drive oncology application development. Cardiology needs advanced imaging technologies together with enhanced early diagnosis methods. Neurology applications help discover various complex brain disorders. Targeted imaging brings attention to infectious diseases while advanced diagnostic systems and dedicated treatment methods help study rare diseases.

Oncology maintains dominance as healthcare systems prioritize accurate tumor identification and response evaluation. The healthcare sector adopts cardiology and neurology technologies because of the rising number of chronic medical conditions. Infectious and rare disease applications expand gradually, supported by research efforts and improved access to diagnostic technologies that enhance disease understanding and treatment outcomes.

To learn more about this report,  Download Free Sample Report

By End-User :

The combination of advanced infrastructure and skilled professionals creates a situation where hospitals use their resources more than any other healthcare facility. Diagnostic centers focus on providing imaging services together with their early detection capabilities. Research institutes contribute their knowledge through innovative work and clinical studies. Pharma companies invest in development and commercialization, while other end-users support niche applications and specialized healthcare services.

Hospitals maintain their role as primary healthcare centers because they provide complete treatment services and handle high patient numbers. Diagnostic centers expand their role in early-stage detection and monitoring. Research institutes support pipeline development through their ongoing research activities. The pharmaceutical industry enables product launch through both partnerships and commercializing activities which establish a market that benefits various healthcare sectors.

By Technology :

The PET technology system has become the leading method for detecting metabolic activity because of its exceptional sensitivity. SPECT systems deliver affordable imaging services. MRI systems enable detailed soft tissue imaging, while CT systems boost structural imaging performance. Molecular imaging combines different methods to provide complete understanding of how diseases progress and how treatments work.

The combination of PET and molecular imaging methods creates advanced diagnostic systems that deliver important clinical benefits. MRI and CT systems remain in common use throughout medical facilities to perform structural examinations. SPECT technology maintains its function in budget-conscious settings because it provides access to medical imaging while its accuracy and diagnostic capabilities improve through technological advances.

What are the Main Challenges for the North America Theranostics Market Growth?

The north america theranostics market faces substantial technical and operational difficulties which impede its growth potential. The primary limitation stems from the brief half-life and unstable characteristics of radiopharmaceuticals which require exacting procedures for their safe handling and quick transport. The process of integrating diagnostic imaging with targeted therapies creates performance challenges because it needs special equipment and specific operational procedures. The north america theranostics market experiences limited growth because of two major issues: scattered supply chains and the requirement for precise isotope availability.

The expansion of the north america theranostics market faces increased difficulties because of manufacturing and commercialization obstacles. The production process for theranostic agents requires complete adherence to Good Manufacturing Practice (GMP) regulations through utilization of sophisticated production facilities which demands substantial financial resources. The two elements lead to increased production expenses which force market participants to decrease their prices. 

The time-consuming and intricate nature of regulatory approval procedures results in product launch delays which impact commercialization speed. The current market restrictions prevent smaller businesses from entering the north america theranostics market while they attempt to grow their operations within the industry.

Infrastructure and workforce shortages create obstacles which hinder the adoption process. The combination of limited specialized imaging center access together with insufficient nuclear medicine expert training restricts organizations from implementing new technologies. The need for mid-tier healthcare facilities faces two main challenges which include funding limitations and reimbursement system uncertainty. The north america theranostics market faces growth limitations because of two factors which include competition from other precision medicine solutions and changes to regulatory requirements.

Regional Insights

The North America Theranostics Market experiences continuous growth because healthcare systems in the region provide strong support while medical professionals increasingly adopt targeted treatment methods. The implementation of diagnostic techniques that operate together with therapeutic solutions allows healthcare providers to achieve superior results with their patients. The healthcare industry will continue to adopt advanced imaging technologies along with radiopharmaceuticals because medical professionals require solutions that provide accurate and timely disease management.

North America holds its dominant market position because the region has established healthcare systems and invests heavily in medical research activities. The United States serves as a central market hub because it contains major industry players who drive constant technological progress in the sector. Canada contributes to market growth through its rising use of modern diagnostic methods and its healthcare regulations which support innovative technologies and improve access to medical services.

The regional market experiences continuous growth because healthcare spending increases and the medical field develops personalized treatment methods. Clinical environments show increased adoption of theranostics solutions because there is a growing need for quick and precise diagnostic capabilities. The market development process in North America advances through the establishment of nuclear medicine facilities together with their training programs which enhance medical education infrastructure.

Recent Development News

In April 2026, Cardinal Health reported increased revenue from its nuclear and precision medicine division, supported by rising adoption of theranostic radiopharmaceutical distribution services. The growth reflects stronger hospital and oncology network integration across the United States.

Source: https://www.cardinalhealth.com/

In March 2026, Lantheus Holdings reported continued growth in its radiopharmaceutical and theranostics portfolio driven by strong demand for PSMA-targeted imaging agents. The company highlighted increased adoption of prostate cancer diagnostic and therapy-linked imaging solutions across North American cancer centers.

Source: https://www.lantheus.com/

How Can New Companies Establish a Strong Foothold in the North America Theranostics Market?

To establish themselves in the North America theranostics market new companies need to concentrate on specific market segments while developing product innovations that set them apart from existing solutions. Startups can meet clinical needs through their radioligand therapy for oncology and their artificial intelligence diagnostic systems which operate in fast-growing markets without confronting established businesses.

 Companies can achieve market growth through key industry trends by using advanced technologies that include machine learning for imaging analysis and precision dosing. The market value for emerging companies in the North America theranostics market gets established through their specific solutions which address major challenges of delayed diagnosis and restricted treatment options. 

North America theranostics companies need strong partnerships as their primary method for achieving business growth. ,Medical institutions, research organizations and pharmaceutical companies work together with startups to share their clinical information and infrastructure and regulatory knowledge. 

Through research collaborations RayzeBio develops targeted radiopharmaceuticals while Telix Pharmaceuticals achieves business expansion through its licensing and commercialization partnerships. New market entrants use these innovation strategies to improve their processing time for products while establishing their business trustworthiness in strict regulatory conditions.

Companies need to invest in scalable manufacturing facilities and supply chain optimization systems to achieve their long-term growth objectives. The company can better its competitive position through isotope supply constraint solutions and production efficiency improvements and its ability to meet regulatory standards. New players can build sustainable businesses in the north america theranostics market by using technology differences and strategic growth together with their knowledge of future market requirements.

Key North America Theranostics Market Company Insights

The North America Theranostics Market demonstrates ongoing development because healthcare systems now implement methods which combine targeted treatment with precise diagnosis. The market expands because personalized healthcare services gain popularity while cancer cases increase and nuclear medicine usage spreads. Researchers continue to back the region's development through their research work and new imaging technologies which healthcare professionals now use as standard practice.

The North America Theranostics Market develops through diagnostic developers working together with treatment providers because this partnership accelerates the process of creating integrated medical solutions. The market expands its growth potential through regulatory support and financial backing which both assist advanced therapeutic solutions. Medical facilities and specialized treatment centers adopt these medical solutions to enhance patient treatment results and eventually improve overall healthcare delivery. 

The competitive market structure contains established pharmaceutical companies together with specialized diagnostic companies which pursue product advancement and strategic business alliances. The market players use their resources to develop new products and conduct clinical studies and acquire other companies for business expansion. The market environment remains competitive because companies work to develop new products while making their products more accessible and forming partnerships with healthcare organizations to grow their business.

Company List

• Novartis
• GE Healthcare
• Siemens Healthineers
• Roche
• Bayer
• Bracco
• Lantheus
• Cardinal Health
• Curium Pharma
• Pfizer
• AstraZeneca
• Merck
• AbbVie
• Eli Lilly
• Thermo Fisher 

What are the Key Use-Cases Driving the Growth of North America Theranostics Market?

The North American theranostics market experiences its main growth from precise oncology applications which use combined diagnostic testing and specialty treatment methods to create customized cancer therapies. Clinicians use radioligand therapies together with advanced imaging methods which include PET scans to achieve precise tumor detection and provide specific treatment solutions that result in better patient health outcomes. The North America theranostics market has become essential to current oncology procedures because healthcare providers now choose to implement value-based care systems in their operations. 

The North American theranostics market is expanding its market presence beyond oncology through its increasing adoption in both neurology and cardiology fields. Theranostic tools help diagnose and monitor Alzheimer’s disease progression through their ability to use biomarker-based imaging for early detection of neurological disorders. Cardiovascular applications use targeted imaging agents to detect patients who face high risk and to establish their required treatment approaches. The existing diagnostic and treatment gaps in healthcare create real-world applications which lead to increased clinical utility and market expansion.

The North America theranostics market uses artificial intelligence together with digital health platforms to create its primary use case. The combination of AI-driven imaging assessment with predictive modeling tools delivers improved diagnostic results and treatment development which supports widespread healthcare operations. 

Pharmaceutical and biotech companies apply theranostics in their drug development process to enhance clinical trial investigation and patient enrollment procedures. The North America theranostics market uses innovation-based applications to create new business opportunities which enhance its capacity to support precise medical treatment and better healthcare delivery.

North America Theranostics Market Report Segmentation

By Type

• Radiopharmaceuticals
• Companion Diagnostics
• Targeted Therapy
• Imaging Agents
• Biomarkers

By Application

• Oncology
• Cardiology
• Neurology
• Infectious Diseases
• Rare Diseases

By End-User

• Hospitals
• Diagnostic Centers
• Research Institutes
• Pharma

By Technology

• PET
• SPECT
• MRI
• CT
• Molecular Imaging